Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 68462-468

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 68462-468). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ctn10mg18s.jpg (Ctn10mg18s)

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets USP 10 mg by Glenmark Pharmaceuticals Inc., USA. The box contains 18 tablets arranged in 6 cartons, each carton containing 3 orally disintegrating tablets. The label includes storage instructions and a phenylketonurics warning, as well as manufacturer and product details.*

FDA Label Image

Ctn5mg18s.jpg (Ctn5mg18s)

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets USP 5 mg by Glenmark Pharmaceuticals Inc. The label includes dosage strength (5 mg), formulation as orally disintegrating tablets, and package quantity of 18 tablets (6 cartons of 3 tablets each). It displays storage instructions, manufacturer information, and a barcode.*

FDA Label Image

Figure1.jpg (Figure1)

A line graph showing the estimated probability of response over time in hours post-dose for placebo, 5 mg, and 10 mg doses of rizatriptan benzoate tablets. The graph compares response rates, illustrating higher response probabilities for both doses relative to placebo, with the 10 mg dose showing the highest response.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose, comparing placebo with rizatriptan benzoate tablets at 5 mg and 10 mg doses. The vertical axis shows probability percentages from 0% to 100%, and the horizontal axis represents time in hours after dosing.*

FDA Label Image

Figure3.jpg (Figure3)

A line graph depicting the estimated probability of response over time in hours post-dose for rizatriptan benzoate orally disintegrating tablets (ODT) at doses of 5 mg and 10 mg compared to placebo. The vertical axis shows probability percentage, and the horizontal axis shows hours post-dose from 0 to 2. The 10 mg dose shows the highest probability of response, followed by the 5 mg dose, and then placebo.*

FDA Label Image

Figure4.jpg (Figure4)

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose for rizatriptan benzoate orally disintegrating tablets (ODT) at 5 mg and 10 mg doses compared to placebo. The x-axis represents hours post-dose from 0 to 24, and the y-axis shows the estimated probability from 0% to 100%. Three lines indicate the placebo, rizatriptan 5 mg, and rizatriptan 10 mg, illustrating their comparative probabilities over time.*

FDA Label Image

Figure5.jpg (Figure5)

A line graph comparing the percentage responses over time between Rizatriptan Benzoate and placebo. The x-axis represents hours post Stage 2 dose from 0.5 to 2.0 hours, and the y-axis shows percentage with 95% confidence intervals. Rizatriptan Benzoate shows higher values than placebo throughout the time points.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure of rizatriptan benzoate showing the molecular components of rizatriptan and benzoate moieties as represented in the image.*

FDA Label Image

Logo.jpg (Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.